This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Subarachnoid haemorrhage거미막하출혈 (지주막하출혈)

📋 Contents and key points
ItemDetails
A. Classification codesICD-10: I60 (Subarachnoid haemorrhage)  |  Special Copayment Reduction: V191 (Special Copayment Reduction for cerebrovascular disease: 5% copayment for up to 30 days from the registration date)
B. SynonymsSubarachnoid hemorrhage, SAH (subarachnoid hemorrhage), non-traumatic subarachnoid hemorrhage
C. Adult onsetMost common in people in their 40s to 60s; aneurysmal subarachnoid hemorrhage shows a slightly higher frequency in middle-aged women. Sudden, excruciating headache is the characteristic presentation.
1. HistoryAfter description by Giovanni Morgagni in the 18th century, diagnosis was revolutionized by the introduction of CT, and the treatment paradigm shifted with the development of endovascular coil embolization.
2. Causes85% are due to rupture of a cerebral aneurysm; other major causes include arteriovenous malformation, smoking, hypertension, and anticoagulant use.
3. GeneticsAssociated with PKD1/PKD2 variants (polycystic kidney disease) and ELN and COL3A1 variants (connective tissue disorders), and several susceptibility loci have been reported in GWAS studies.
4. General epidemiologyAnnual incidence is about 6~9 per 100,000 population, with high incidence reported in Finland and Japan.
5. PathophysiologySudden rise in intracranial pressure after aneurysm rupture, acute cerebral ischemia, disruption of the blood–cerebrospinal fluid barrier, and delayed cerebral vasospasm are the main pathophysiology.
6. SymptomsSudden 'thunderclap headache', nausea, vomiting, neck stiffness, and decreased consciousness are characteristic, and a warning headache (sentinel headache) may precede it.
7. SignsSigns of meningeal irritation (Kernig, Brudzinski), subhyaloid hemorrhage (Terson syndrome), pupillary dilation, and oculomotor nerve palsy may be observed.
8. ScreeningRegular screening with MRA or CTA is recommended for groups at high risk of unruptured cerebral aneurysm (family history, PKD).
9. DiagnosisNon-contrast head CT is the first-line diagnostic test; if CT is negative, xanthochromia is checked by lumbar puncture, and the aneurysm location is confirmed by CTA/DSA.
10. TreatmentThe aneurysm is occluded by coil embolization or clip ligation, and complications are prevented with nimodipine, fluid therapy, and intracranial pressure management.
11. Prognosis30-day mortality is about 40~50%, and one-third of survivors have neurological disability. Initial neurological status and Fisher grade are the key determinants of prognosis.
12. PreventionSmoking cessation, hypertension control, avoiding heavy drinking, and regular follow-up of high-risk groups for unruptured aneurysm are the main prevention strategies.
13. ReferencesFeigin VL, et al. Stroke epidemiology: a review of population-based studies of incidence, prevalence, and case-fatality in the late 20th century. Lancet Neurol. 2003 … and 9 other papers

1. History

The history of subarachnoid hemorrhage (SAH) dates back to the 18th century. In 1761, the Italian pathologist Giovanni Battista Morgagni left the first systematic description linking blood accumulation on the brain surface with the clinical symptoms of headache and loss of consciousness through autopsy studies. However, diagnosis during life remained very difficult until the early 20th century, and most cases were confirmed at autopsy. In 1891, when Heinrich Quincke introduced the technique of lumbar puncture, diagnosis during life through bloody cerebrospinal fluid (bloody CSF) first became possible.

The association between aneurysm and SAH was first reported by Sir Byrom Bramwell in 1859, and in 1924 Charles Symonds first systematically described the clinical syndrome of SAH. The history of surgical treatment began in 1937 when Walter Dandy first successfully performed cerebral aneurysm clip ligation (surgical clipping) via craniotomy. Subsequently, with the development of microscope technology, microneurosurgery was standardized in the 1960s–70s.

A groundbreaking turning point in diagnostic imaging was the introduction of computed tomography (CT) in the 1970s. After Ambrose first reported CT findings in SAH in 1974, CT became established as the standard test for diagnosing SAH. In 1991, when Guido Guglielmi developed endovascular coil embolization and began applying it clinically, SAH treatment entered a new era. The ISAT (International Subarachnoid Aneurysm Trial) published in 2002 demonstrated in a randomized controlled trial that coil embolization significantly lowered mortality and disability compared with surgical clip ligation, playing a decisive role in establishing endovascular treatment as the first-line treatment strategy for SAH.

In Korea, surgical treatment of SAH in neurosurgery became widespread from the 1980s, and treatment outcomes improved greatly with the spread of endovascular treatment after the 1990s. Since the 2000s, advances in the understanding of the pathophysiology of cerebral vasospasm and delayed cerebral ischemia (DCI) and in prevention strategies have contributed to improving the long-term prognosis of SAH.


2. Causes

The most common cause of subarachnoid hemorrhage is rupture of an intracranial aneurysm, accounting for about 85% of all SAH. A cerebral aneurysm is a saccular or fusiform dilatation formed by focal weakening of the vessel wall, occurring most often at flow bifurcations such as the internal carotid–posterior communicating artery junction, the anterior communicating artery, and the middle cerebral artery bifurcation. Known risk factors for aneurysm rupture include aneurysm size (7mm or more), irregular shape, smoking, hypertension, heavy drinking, and sympathetic stimulation (extreme exertion, sexual activity, Valsalva maneuver during defecation).

The remaining 15% of SAH is due to non-aneurysmal causes, of which about 10% is perimesencephalic non-aneurysmal SAH (PNASH) with a relatively benign course. Other causes include cerebral arteriovenous malformation (AVM), dural arteriovenous fistula (dural AVF), spinal vascular malformations, coagulation disorders (hemophilia, anticoagulant use), sickle cell anemia, infectious aneurysm (mycotic aneurysm) due to fungal or bacterial endocarditis, and brain tumors (especially glioblastoma or metastatic cancer). Sympathomimetic drugs such as cocaine and amphetamines can also cause SAH through cerebral vasospasm or aneurysm rupture.

A rare but important cause is reversible cerebral vasoconstriction syndrome (RCVS), which causes SAH confined to the cortical surface together with recurrent thunderclap headaches. SAH occurring during pregnancy or immediately after delivery is in some cases associated with eclampsia, spontaneous coronary artery dissection, or RCVS. Because traumatic SAH is classified separately in the ICD-10 system (S06.6), the I60 code applies to non-traumatic SAH.


3. Genetics

Cerebral aneurysm, the main cause of subarachnoid hemorrhage, has a substantial genetic contribution. In twin studies, the concordance of aneurysm is significantly higher in monozygotic than dizygotic twins, confirming a genetic predisposition. The genetic disease most strongly associated with the development of cerebral aneurysm is autosomal dominant polycystic kidney disease (ADPKD), and cerebral aneurysms develop in about 10~15% of patients with variants in the PKD1 or PKD2 gene.

Gene variants associated with connective tissue disorders are also important. COL3A1 (type III collagen) variants associated with Ehlers-Danlos syndrome type IV, FBN1 variants associated with Marfan syndrome, and abnormalities of the elastin gene (ELN) increase vessel wall fragility and promote aneurysm formation. The risk of cerebrovascular abnormalities is also known to be increased in neurofibromatosis type 1 (NF1).

Genome-wide association studies (GWAS) have identified several susceptibility loci associated with sporadic cerebral aneurysm. Representative examples are CDKN2A-CDKN2B (9p21), SOX17 (8q11), and RBBP8 (18q11), involved respectively in regulation of cell proliferation, vascular development, and DNA damage response. When there are two or more patients with cerebral aneurysm among first-degree relatives, the risk increases 4~7 times compared with the general population, so genetic counseling and screening are recommended for those with a family history of familial cerebral aneurysm.


4. General epidemiology

The worldwide annual incidence of subarachnoid hemorrhage is about 6~9 per 100,000 population; it accounts for about 5% of all strokes but contributes about 25% of stroke-related deaths. Incidence varies considerably by region; it is particularly high in Finland and Japan, reaching about 20 per 100,000 population, and relatively low in China and South Asia. These differences are presumed to be due to differences in genetic factors, smoking rates, and prevalence of hypertension.

According to Korean data, the annual incidence of SAH is about 13~20 per 100,000, somewhat higher than the global average, which is analyzed as being partly influenced by the prevalence of hypertension and smoking rate among Koreans. It occurs most often in people in their 40s to 60s, with a mean age of onset of around 55. By sex, it is slightly more common in men before age 55, but the proportion of women increases after age 55. This may be related to the loss of the vascular protective effect with decreased estrogen after menopause.

Worldwide, the incidence of SAH has shown a gradual decreasing trend over the past several decades, which is attributed to improved hypertension treatment rates and decreased smoking rates. Mortality has also improved greatly compared with the past: 30-day mortality, which reached 60% in the 1980s, has now fallen to around 40%. This is interpreted as owing to advances in diagnostic imaging technology such as CT, the spread of endovascular treatment, and improved intensive care unit management.


5. Pathophysiology

The pathophysiology of SAH due to cerebral aneurysm rupture is multistep and complex. Immediately after rupture, blood rapidly enters the subarachnoid space, momentarily raising intracranial pressure (ICP) sharply and causing a precipitous drop in cerebral perfusion pressure. The resulting acute global cerebral ischemia is the main mechanism of initial loss of consciousness. At the same time, the sympathetic nervous system becomes overactivated, inducing cardiac complications (neurogenic pulmonary edema, Takotsubo cardiomyopathy, ECG abnormalities).

When blood enters the subarachnoid space, large amounts of oxyhemoglobin, bilirubin, and cytokines are released along with red cell lysis. These substances act directly on vascular smooth muscle or induce endothelial dysfunction, causing delayed cerebral vasospasm. Vasospasm peaks between 4 and 14 days after hemorrhage and causes clinical neurological deterioration in about 30~40% of survivors. This is called 'delayed cerebral ischemia (DCI)' and is an important secondary injury mechanism of SAH.

Hydrocephalus is another important complication; in the acute phase, communicating hydrocephalus develops due to impaired CSF absorption by blood, and in the chronic phase, normal pressure hydrocephalus may appear due to arachnoid fibrosis. Hyponatremia arises from cerebral salt wasting due to natriuretic peptides (BNP, ANP) secreted by the brain or from the syndrome of inappropriate antidiuretic hormone secretion (SIADH). Because hyponatremia worsens cerebral edema, active correction is needed.


6. Symptoms

The most characteristic symptom of subarachnoid hemorrhage is a suddenly occurring excruciating headache, which patients often describe as "the worst headache of my life" or "a headache like being hit on the head with a hammer." This is called 'thunderclap headache' and is characterized by reaching peak intensity within seconds. The headache spreads from the frontal to the occipital region, or to the neck and back, and is worsened by movement, light, and sound.

Nausea and vomiting accompany the headache in about 70%, due to raised intracranial pressure. Changes in consciousness are very common, ranging in degree from transient loss of consciousness to deep coma. Seizures occur in about 15~20% of SAH patients and are one of the risk factors for early rebleeding. Photophobia and phonophobia are also commonly reported symptoms.

In some patients, a 'sentinel headache' appears 2~8 weeks before the full SAH. This is presumed to be due to a minor leak from the aneurysm and is identified retrospectively in about 20~40% of all SAH patients. Sentinel headaches are often mistaken for migraine or tension-type headache and frequently pass without proper evaluation, making this a representative clinical situation that emphasizes the need for active evaluation of sudden severe headache. In addition, focal neurological deficits may appear depending on the location of the aneurysm, and with rupture of a posterior communicating artery aneurysm, oculomotor nerve palsy with ipsilateral pupillary dilation may occur.


7. Signs

On physical examination, the main sign suggesting subarachnoid hemorrhage is the meningeal irritation sign. Nuchal rigidity develops within a few hours after hemorrhage, with strong resistance felt when the neck is flexed. Kernig's sign is strong resistance and pain when attempting to extend the knee with the hip flexed at 90 degrees, and Brudzinski's sign is reflex flexion of the hips and knees when the neck is flexed. These meningeal irritation signs are caused by meningeal irritation by blood, and in some cases appear fully only after 12~24 hours have passed since the hemorrhage.

Terson syndrome, found on fundoscopy, is subhyaloid hemorrhage or vitreous hemorrhage caused by central retinal vein occlusion due to a sudden rise in intracranial pressure. It is observed in about 20~25% of SAH patients, and prognosis is known to be worse when Terson syndrome is present. Fundoscopy should be performed as part of the initial evaluation in all patients with suspected SAH.

For neurological severity grading, the Hunt-Hess grade (I~V) is the most widely used clinically, and the WFNS (World Federation of Neurosurgical Societies) grade is more objective, being based on GCS score and motor deficit. In terms of vital signs, hypertension is the most commonly observed (due to sympathetic overactivity), and ECG abnormalities (QT prolongation, ST segment changes, T-wave inversion) and arrhythmias are frequent. These ECG abnormalities reflect neurogenic myocardial injury and may require differentiation from actual coronary artery disease.


8. Screening

Screening of the general population for subarachnoid hemorrhage itself is not recommended, but screening of high-risk groups for unruptured intracranial aneurysm is clinically important. For familial cerebral aneurysm, the occurrence of cerebral aneurysm or SAH in two or more first-degree relatives is defined as 'familial aneurysm clustering,' and regular MRA screening after age 20 is considered for members of such families.

For patients with polycystic kidney disease (ADPKD), a first cerebrovascular imaging study (MRA or CTA) is recommended after age 40, and follow-up every 5 years is recommended even if no aneurysm is found. Regular cerebrovascular imaging evaluation is also needed in patients with hereditary vascular diseases such as Marfan syndrome, Ehlers-Danlos syndrome type IV, and tuberous sclerosis. In addition, regular follow-up imaging is needed in patients with a past history of SAH or treated cerebral aneurysms to check for development of new aneurysms.

When an unruptured cerebral aneurysm is found, management uses the PHASES score (Population, Hypertension, Age, Size of aneurysm, Earlier SAH, Site of aneurysm) to estimate the 5-year risk of rupture, and observation or preventive treatment is decided by combining rupture risk, treatment risk, and patient preference. In general, preventive treatment is actively considered for cerebral aneurysms of 7mm or more, irregular shape, rapid growth, location at the posterior communicating or anterior communicating artery, and younger patient age.


9. Diagnosis

In patients with suspected SAH, non-contrast brain CT is the test that should be performed first. When performed within 6 hours of symptom onset, CT sensitivity exceeds 98%, but sensitivity declines with time, decreasing to about 85% after 12 hours and 70% or less after 24 hours. On CT, SAH appears as a hyperdense signal in the subarachnoid space, especially in the basal cisterns and Sylvian fissure. The Fisher grade (I~IV) classifies the amount of hemorrhage based on CT findings and is used to predict the risk of vasospasm.

When SAH is not confirmed on CT but is strongly suspected clinically, lumbar puncture is performed to analyze CSF. SAH can be diagnosed if yellow discoloration (xanthochromia) is observed in the supernatant after centrifugation of bloody CSF. Because xanthochromia is observed from 2 hours to 2 weeks after hemorrhage, the test is reliable only if performed after an appropriate time has elapsed since symptom onset. In addition, if the red cell count remains the same across 4 tubes (unlike the decrease seen in a traumatic tap), SAH is likely.

To evaluate the cause of bleeding, CT angiography (CTA) or MR angiography (MRA) is performed. CTA can detect most aneurysms with rapid examination time and high resolution (sensitivity 98%) and is widely used as the first-line vascular imaging in emergencies. Digital subtraction angiography (DSA) for confirmation is still used as the standard test for understanding aneurysm anatomy and treatment planning, and must be performed especially when no aneurysm is found on CTA. Blood tests—CBC, coagulation tests, electrolytes, cardiac enzymes (troponin), and BNP—are checked to evaluate complications.


10. Treatment

Treatment of SAH rests on two pillars: treatment of the aneurysm and prevention of complications. Early occlusion of the aneurysm to prevent rebleeding is the top priority, and the main methods are endovascular coiling and surgical clipping. Based on the ISAT results, coil embolization is preferentially recommended for aneurysms anatomically suitable for coiling. However, surgical clipping is preferred for middle cerebral artery aneurysms, wide-neck aneurysms, and cases requiring decompression of intracranial pressure due to an accompanying hematoma.

A key treatment for preventing complications is administration of nimodipine. Nimodipine, a calcium channel blocker, is given orally (60mg every 4 hours) or intravenously for 21 days starting immediately after confirmation of hemorrhage to prevent DCI due to vasospasm. For fluid therapy, the principle is to maintain euvolemia to prevent cerebral vasospasm, and the formerly used hypervolemic hemodilution hypertensive therapy (Triple-H therapy) is currently not recommended due to lack of evidence. External ventricular drainage (EVD) may be needed to manage intracranial pressure and is effective especially when hydrocephalus is present.

For blood pressure management during hospitalization, maintaining systolic blood pressure below 160mmHg is recommended before the aneurysm is treated, and after treatment appropriate blood pressure is maintained to prevent DCI. Hyponatremia is corrected with normal saline or 3% hypertonic saline, but fluid therapy should be decided after differentiating cerebral salt wasting from SIADH. Evidence for prophylactic antiseizure medication is currently limited, and the trend is to recommend its therapeutic use only when seizures occur. Comprehensive supportive care at the intensive care unit level, including temperature control, blood glucose management, and nutritional support, is essential.


11. Prognosis

Subarachnoid hemorrhage is one of the stroke types with the poorest prognosis, with overall mortality including prehospital deaths reaching about 40~50%. Deaths within 24 hours of onset account for about 10~15% of all deaths, due to acute brain injury and cardiopulmonary complications from the initial hemorrhage. About one-third of survivors have serious neurological disability (hemiparesis, cognitive decline, speech disturbance), and complete functional recovery occurs in only about 30~40% of survivors.

The main factors determining prognosis are initial neurological status (Hunt-Hess grade or WFNS grade), amount of hemorrhage (Fisher grade), aneurysm location and size, patient age, duration of cerebral ischemia before arrival at a medical institution, and occurrence of rebleeding. In particular, rebleeding occurs with a frequency of 4~14% within 24 hours in untreated aneurysms, and mortality with rebleeding rises sharply to over 70%. Therefore, early aneurysm treatment is key to improving prognosis.

DCI has an important effect on the long-term prognosis of survivors, and cognitive decline, depression, and reduced quality of life increase markedly in patients who have experienced DCI. Hydrocephalus develops as a chronic complication in about 15~20% of SAH patients and requires a ventriculoperitoneal shunt. In the long term, SAH survivors need continued follow-up for neurocognitive impairment, epilepsy, and recurrent SAH (development of new aneurysms). Although prognosis has gradually improved with advances in treatment technology over the past 20 years, it remains a severe cerebrovascular disease with considerable morbidity and mortality.


12. Prevention

Active treatment of hypertension, the most important risk factor for subarachnoid hemorrhage, is key to preventing SAH. To keep blood pressure below 130/80 mmHg, antihypertensive drugs are used as needed together with lifestyle improvement (low-salt diet, weight loss, regular exercise). Smoking cessation reduces the risk of SAH by about 50% and is the preventive behavior to be emphasized most. In smokers, the risk of aneurysm rupture increases 2~3 times compared with nonsmokers.

Excessive drinking (5 or more drinks per week) is also an independent risk factor for SAH, so moderation of alcohol is recommended. Use of sympathomimetic stimulants such as cocaine and amphetamines can cause aneurysm rupture through acute surges in blood pressure and should be completely prohibited. Some studies have suggested an association between oral contraceptives and SAH risk, so they should be prescribed cautiously in high-risk women (hypertension, smoking, family history). Regular aerobic exercise of moderate intensity promotes cardiovascular health and controls blood pressure, contributing to lowering SAH risk.

In patients in whom a cerebral aneurysm has already been found, prevention involves an individualized strategy that compares the risk of rupture with the risk of treatment. Small aneurysms (less than 5mm) in benign locations undergo imaging follow-up at intervals of 6 months to 1 year, and preventive treatment is considered when growth is confirmed or risk factors are combined. Coil embolization or clip ligation is applied as the treatment method, and recently new endovascular treatment options using flow diverters (e.g., the Pipeline embolization device) are also being used. Early detection and preventive treatment through regular MRA screening and genetic counseling of those with familial risk factors are important.


13. References

  1. Feigin VL, Lawes CM, Bennett DA, Anderson CS. Stroke epidemiology: a review of population-based studies of incidence, prevalence, and case-fatality in the late 20th century. Lancet Neurol. 2003;2(1):43-53. DOI: 10.1016/S1474-4422(03)00266-7. PMID: 12849300.

  2. Molyneux AJ, Kerr RS, Yu LM, et al. International subarachnoid aneurysm trial (ISAT) of neurosurgical clipping versus endovascular coiling in 2143 patients with ruptured intracranial aneurysms: a randomised comparison of effects on survival, dependency, seizures, rebleeding, subgroups, and aneurysm occlusion. Lancet. 2005;366(9488):809-817. DOI: 10.1016/S0140-6736(05)67214-5. PMID: 16139655.

  3. Bederson JB, Connolly ES Jr, Batjer HH, et al. Guidelines for the management of aneurysmal subarachnoid hemorrhage: a statement for healthcare professionals from a special writing group of the Stroke Council, American Heart Association. Stroke. 2009;40(3):994-1025. DOI: 10.1161/STROKEAHA.108.191395. PMID: 19164800.

  4. Connolly ES Jr, Rabinstein AA, Carhuapoma JR, et al. Guidelines for the management of aneurysmal subarachnoid hemorrhage: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2012;43(6):1711-1737. DOI: 10.1161/STR.0b013e3182587839. PMID: 22556195.

  5. Rinkel GJ, Djibuti M, Algra A, van Gijn J. Prevalence and risk of rupture of intracranial aneurysms: a systematic review. Stroke. 1998;29(1):251-256. DOI: 10.1161/01.STR.29.1.251. PMID: 9445359.

  6. van Gijn J, Kerr RS, Rinkel GJ. Subarachnoid haemorrhage. Lancet. 2007;369(9558):306-318. DOI: 10.1016/S0140-6736(07)60153-6. PMID: 17258671.

  7. Hop JW, Rinkel GJ, Algra A, van Gijn J. Case-fatality rates and functional outcome after subarachnoid hemorrhage: a systematic review. Stroke. 1997;28(3):660-664. DOI: 10.1161/01.STR.28.3.660. PMID: 9056628.

  8. Maher M, Schweizer TA, Macdonald RL. Treatment of spontaneous subarachnoid hemorrhage: guidelines and gaps. Stroke. 2020;51(4):1326-1332. DOI: 10.1161/STROKEAHA.119.025997. PMID: 32146888.

  9. Etminan N, Chang HS, Hackenberg K, et al. Worldwide incidence of aneurysmal subarachnoid hemorrhage according to region, time period, blood pressure, and smoking prevalence in the population: a systematic review and meta-analysis. JAMA Neurol. 2019;76(5):588-597. DOI: 10.1001/jamaneurol.2019.0006. PMID: 30958504.

  10. Kim JH, Yi HJ, Bak KH, Ko Y. Clinical characteristics and treatment outcomes of spontaneous subarachnoid hemorrhage in Korean patients. J Korean Neurosurg Soc. 2020;63(3):381-389. DOI: 10.3340/jkns.2019.0211. PMID: 32313488.